Key Takeaways
- Star Therapeutics will present its innovative pipeline, including VGA039, at the J.P. Morgan Healthcare Conference.
- The conference presentation will provide insights into VGA039’s potential as a universal hemostatic therapy for bleeding disorders.
- CEO Adam Rosenthal will deliver the presentation on January 14, 2025, in San Francisco.
Star Therapeutics, a clinical-stage biotechnology company specializing in antibody innovation, has announced its participation in the 43rd J.P. Morgan Healthcare Conference. This premier event will take place from January 13-16, 2025, in San Francisco, California. Adam Rosenthal, Ph.D., the company’s CEO and Founder, will present an overview of Star Therapeutics’ mission, pipeline, and its lead drug candidate, VGA039.
The presentation is scheduled for Tuesday, January 14, at 9:30 a.m. PT at The Westin St. Francis. Dr. Rosenthal will highlight the company’s progress in developing VGA039, a groundbreaking monoclonal antibody therapy designed to address von Willebrand disease (VWD) and other bleeding disorders.
VGA039: A Transformative Therapy for Bleeding Disorders
VGA039 represents a significant advancement in the treatment of bleeding disorders. The monoclonal antibody targets Protein S, a critical component in restoring balance to the blood clotting process. With its unique mechanism of action, VGA039 has the potential to become a universal hemostatic therapy, offering treatment solutions for numerous bleeding conditions.
Designed as a subcutaneous, self-administered therapy, VGA039 aims to simplify treatment regimens, reduce patient burden, and improve overall outcomes. Star Therapeutics is optimistic about VGA039’s potential to transform the management of von Willebrand disease (VWD) and other related conditions.
About Star Therapeutics
Star Therapeutics is committed to creating life-changing therapies through innovative antibody discovery and development. Based in South San Francisco, the company focuses on addressing unmet needs in hematology and immunology. By leveraging expertise in antibody innovation, Star Therapeutics is unlocking therapeutic opportunities in overlooked areas of biology, aiming to address multiple diseases with single therapies.
Backed by leading life sciences investors, Star Therapeutics continues to advance its pipeline with a strong emphasis on scientific excellence and transformative potential.
The J.P. Morgan Healthcare Conference offers Star Therapeutics a platform to connect with industry leaders, investors, and stakeholders. The company’s participation underscores its commitment to innovation in biotechnology and advancing treatments for unmet medical needs. Dr. Rosenthal’s presentation will provide a unique opportunity to showcase Star Therapeutics’ vision and its progress toward delivering life-changing therapies for patients worldwide.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
